If you have colorectal cancer that has spread to other parts of the body despite standard chemotherapy, a healthcare provider may prescribe Vectibix. This drug is only used for certain types of cancer that have a protein called epidermal growth factor receptor. Vectibix helps slow down the progression of cancer by binding to these receptors, slowing down the growth of the cells.
What Is Vectibix Used For?Vectibix® (panitumumab) is a prescription medication approved for the treatment of colorectal cancer, a type of cancer that occurs when cancerous cells form in the tissue of the large intestine (colon) or rectum. It is given as an intravenous (IV) infusion, which is a slow injection into a vein.
Vectibix is reserved for use when colorectal cancer has spread beyond the colon or rectum to other parts of the body despite treatment with standard chemotherapy, such as:
- Fluorouracil (Adrucil®, Carac®, Efudex®, Fluoroplex®, also known as 5-FU)
- Oxaliplatin (Eloxatin®)
- Irinotecan (Camptosar®).
Colorectal cancer that has spread is called metastatic colorectal cancer, or stage IV colorectal cancer.
This medicine is meant to be used as a single agent. It is not approved for use in combination with other chemotherapy medicines. It is also designed for use only in cancers that have a protein called the epidermal growth factor receptor (EGFR) on the surface of the cancer cells. Your healthcare provider will test your cancer for EGFR protein expression.
Vectibix may extend the time until metastatic colorectal cancer progresses. It has not been shown to extend overall survival or improve cancer symptoms.
Vectibix is not designated for use in people with KRAS mutation-positive metastatic colorectal cancer or in people where the KRAS status is unknown. People with tumors that have the KRAS mutation have not shown a treatment benefit with Vectibix.